Table 2

Baseline characteristics of 8 AT(N) profile groups

AT(N)tauA-T-(N)−A-T-(N)+A-T+(N)−A-T+(N)+A+T-(N)−A+T-(N)+A+T+(N)−A+T+(N)+P value
No (%)52 (29.4)3 (1.7)4 (2.3)3 (1.7)37 (20.9)4 (2.3)10 (5.6)64 (36.2)
Age, years (IQR)67 (9)77 (4)74 (5)75 (3)71 (10)74 (8)73 (9)74 (9)0.109
Female, n (%)23 (44.2)2 (66.7)1 (25.0)2 (66.7)18 (48.6)1 (25.0)4 (40.0)36 (56.3)0.692
Education, years (IQR)14 (4)16 (2)16 (0)16 (2)12 (4)10 (4)13 (3)13 (4)0.091
APOE ε4 allele (%)<0.001
 049 (94.2)2 (66.7)3 (75.0)2 (66.7)16 (43.2)1 (25.0)3 (30.0)19 (29.7)
 13 (5.8)1 (33.3)1 (25.0)1 (33.3)18 (48.6)2 (50.0)6 (60.0)31 (48.4)
 20 (0)0 (0)0 (0)0 (0)3 (8.1)1 (25.0)1 (10.0)14 (21.9)
Clinical status, n (%)<0.001
 CU31 (59.6)1 (33.3)2 (50.0)1 (33.3)7 (18.9)0 (0)1 (10.0)3 (4.7)
 MCI21 (40.4)2 (66.7)1 (25.0)2 (66.7)14 (37.8)2 (50.0)5 (50.0)35 (54.7)
 ADD0 (0)0 (0)1 (25.0)0 (0)16 (43.2)2 (50.0)4 (40.0)26 (40.6)
MMSE (IQR)29 (2)27 (2)28 (3)25 (3)25 (6)24 (2)25 (2)25 (5)<0.001
ADAS-Cog (IQR)9.4 (9.1)20.7 (10.3)9.7 (7.4)23.0 (10.7)21.3 (12.7)25.8 (1.4)22.2 (10.8)23.3 (9.6)<0.001
CDR-SB (IQR)0 (0.5)2.5 (1.5)0.5 (0.5)0.5 (1.5)1.5 (2.5)2.8 (2.0)2.0 (2.0)2.0 (2.5)<0.001
FAQ (IQR)0 (0)9 (8)0 (3)0 (8)5 (6)6 (2)4 (6)5 (10)<0.001
Aβ PET, n (%)<0.001
 Negative34 (100)1 (50.0)1 (100)1 (33.3)2 (14.3)0 (0)0 (0)3 (10.0)
 Positive0 (0)1 (50.0)0 (0)2 (66.7)12 (85.7)1 (100)3 (100)27 (90.0)
BL Aβ42, pg/mL (IQR)485.2 (101.7)373.7 (99.1)541.2 (144.8)431.5 (148.8)240.7 (99.9)198.8 (88.8)254.8 (73.4)234.0 (65.0)<0.001
BL p-tau, pg/mL (IQR)19.2 (4.5)25.7 (2.2)37.8 (7.1)35.3 (10.4)22.1 (6.2)28.1 (1.9)38.2 (6.8)47.3 (23.4)<0.001
BL t-tau, pg/mL (IQR)58.4 (29.6)132.0 (37.4)76.1 (14.3)140.7 (14.3)71.7 (37.9)118.2 (42.0)89.2 (30.1)151.7 (57.2)<0.001
BL NfL, pg/mL (IQR)2421.6 (1344.7)5055.5 (3295.7)2663.6 (1101.9)2479.2 (2428.3)2959.0 (1508.0)7850.2 (13779.4)2874.5 (818.1)3515.2 (1130.2)<0.001
AT(N)NfLA-T-(N)-A-T-(N)+A-T+(N)-A-T+(N)+A+T-(N)+A+T-(N)+A+T+(N)-A+T+(N)+P value
No (%)39 (20.1)16 (8.2)5 (2.6)2 (1.0)20 (10.3)21 (10.8)32 (16.5)42 (21.6)
Age, years (IQR)66 (8)76 (12)74 (4)76 (1)69 (7)75 (8)72 (10)74 (8)0.001
Female, n (%)18 (46.2)7 (43.8)3 (60.0)0 (0)12 (60.0)7 (33.3)18 (56.3)22 (52.4)0.498
Education, years (IQR)14 (4)13 (4)16 (0)20 (4)12 (2)12 (5)12 (4)14 (4)0.090
APOE ε4 allele (%)<0.001
 037 (94.9)14 (87.5)4 (80.0)1 (50.0)11 (55.0)6 (28.6)8 (25.0)14 (33.3)
 12 (5.1)2 (12.5)1 (20.0)1 (50.0)9 (45.0)11 (52.4)17 (53.1)20 (47.6)
 20 (0)0 (0)0 (0)0 (0)0 (0)4 (19.0)7 (21.9)8 (19.0)
Clinical status, n (%)<0.001
 CU27 (69.2)5 (31.3)3 (60.0)0 (0)7 (35.0)0 (0)4 (12.5)0 (0)
 MCI12 (30.8)11 (68.8)2 (40.0)1 (50.0)8 (40.0)8 (38.1)18 (56.3)22 (52.4)
 ADD0 (0)0 (0)0 (0)1 (50.0)5 (25.0)13 (61.9)10 (31.3)20 (47.6)
MMSE (IQR)29 (2)28 (3)30 (3)24 (0)25 (5)24 (5)25 (4)24 (5)<0.001
ADAS-Cog (IQR)8.3 (7.5)13.7 (12.4)9.7 (15.6)21.9 (5.2)16.0 (16.0)24.7 (5.4)23.2 (9.6)23.7 (8.9)<0.001
CDR-SB (IQR)0 (0.5)1.0 (1.0)0.5 (1.0)2.0 (1.5)1.5 (2.5)2.5 (3.0)2.3 (2.5)2.0 (2.0)<0.001
FAQ (IQR)0 (0)2 (2)0 (3)4 (4)5 (7)6 (5)5 (7)5 (10)<0.001
Aβ PET, n (%)<0.001
 Negative25 (100)10 (90.9)2 (66.7)0 (0)2 (22.2)0 (0)1 (7.7)2 (10.0)
 Positive0 (0)1 (9.1)1 (33.3)1 (100)7 (77.8)6 (100)12 (92.3)18 (90.0)
BL Aβ42, pg/mL (IQR)479.7 (84.3)501.3 (139.4)568.2 (230.8)486.3 (54.9)214.7 (137.8)240.7 (66.2)241.9 (34.2)237.5 (80.7)<0.001
BL p-tau, pg/mL (IQR)19.2 (4.1)21.0 (7.2)35.3 (4.0)41.0 (9.8)22.4 (7.0)23.0 (7.0)40.5 (13.7)44.4 (21.4)<0.001
BL t-tau, pg/mL (IQR)54.6 (24.4)88.0 (30.6)82.8 (43.4)114.3 (33.7)59.1 (23.6)92.4 (15.7)128.3 (43.5)155.3 (68.3)<0.001
BL NfL, pg/mL (IQR)2106.9 (1118.0)4147.5 (1243.0)2464.2 (167.0)5922.1 (1398.6)2414.6 (570.9)3901.7 (3674.1)2640.4 (522.3)3785.2 (943.6)<0.001
  • Numbers are median (IQR) for continuous variables and raw number (percentage) for categorical variables.

  • Differences in baseline characteristics of participants across 8 AT(N) profiles were first assessed using Kruskal-Wallis rank sum test for continuous variables, or a χ2 test for categorical variables.

  • ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; ADD, Alzheimer’s disease dementia; Aβ, β-amyloid; BL, baseline; CDR-SB, sum of boxes of the Clinical Dementia Rating; CU, cognitively unimpaired subjects; FAQ, Functional Assessment Questionnaire; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NfL, neurofilament light chain; p-tau181, tau phosphorylated at threonine 181; t-tau, total tau.